Intravitreal Injections-related Anxiety

Study Overview
=================
Brief Summary
-----------------
Intravitreal injection of Ranibizumab (Lucentis, Genentech) is clinically indicated for patients with wet age-related macular degeneration (AMD) An disadvantage of this technique is the anxiety and discomfort which patients often experience due to the idea of getting a needle in the eye. In addition, a recent case study indicated the importance of patient education in achieving positive outcomes from intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. The purpose of our study is to determine whether visual education on AMD and intravitreal injection can reduce patients' anxiety prior to the treatment, and lessen the impact of socioeconomical status on their understanding of the treatment and prognosis.

Detailed Description
-----------------
The use of intravitreal injections of Ranibizumab (Lucentis, Genentech) is becoming increasing common for the management of age-related macular degeneration (AMD). It is therefore important to acknowledge and address patients' anxiety due to anticipated discomfort from the idea of getting a needle in the eye. In addition, visual provision of information at diagnosis concerning long-term treatment expectation may enhance the informed consent process. The use of visual aids may also accommodate patients of different educational background when presented with new and complex treatment information. The purpose of our study is to determine whether visual education on AMD and intravitreal injection can reduce patients' anxiety prior to the treatment, and lessen the impact of socioeconomical status on their understanding of the treatment and prognosis. Although this tool will be developed in the context of injection-requiring retinal diseases, it has applications in the care of disease requiring long-term treatments.

Official Title
-----------------
A Visual Approach to Reducing Anxiety and Improving Knowledge Transfer for Patients Receiving Intravitreal Injections

Conditions
-----------------
Age-related Macular Degeneration

Intervention / Treatment
-----------------
* Behavioral: Printed materials
* Behavioral: Video


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older AMD patients requiring intravitreal injections Exclusion Criteria: Unable to read or comprehend English Any contraindications to intravitreal injections, such as IOP elevations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>AMD-related information is not given to patients randomized to the control group. | |
| Active Comparator: Video materials<br>Educational materials are presented in through a video (audio and visual) | Behavioral: Video<br>* AMD-related information is presented as in the form of a video<br>|
| Active Comparator: Print materials<br>Educational materials are presented in the format of printed brochure (visual) | Behavioral: Printed materials<br>* AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anxiety |  | Cross-sectional study, where questionnaires will be completed on the same day of clinic visit. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge of AMD |  | Cross-sectional study, where questionnaires will be completed on the same day of clinic visit. |